Listen to Sten R Sorensen, CEO of Cereno Scientific, go into depth about the company's new strategic focus and share their impressions from the company's capital markets day.
The temperature at Cereno Scientific after significant news
Cereno Scientific has recently announced the selection of a rare disease, idiopathic pulmonary fibrosis, as the target indication for its second drug candidate, CS014. Together with the new results for its lead candidate, CS1, this marks a clear shift in the company's strategy and focus: rare diseases that currently leave patients without effective treatment options.